ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0009688

myasthenia gravis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. myasthenia gravis. Diseases, record MONDO_0009688. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009688

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
myasthenia gravis
Open Targets
Open Targets ID
MONDO_0009688
Open Targets
Other names
acquired myasthenia, autoimmune myasthenia gravis
Open Targets
Disease Ontology
DOID:437
Disease Ontology
MeSH
D009157
MeSH
NCI Thesaurus
C60989
NCI Thesaurus
Orphanet
ORPHA:589
Orphanet
Highest stage of its drugs
Approval, for 15 of its 77 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs77

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
EFGARTIGIMOD ALFACHEMBL4297551ProteinApprovalEMA Human Drugs, FDA, PMDA and TTD241918Drugs and targets
ZILUCOPLANCHEMBL4298207ProteinApprovalEMA Human Drugs1199Drugs and targets
ROZANOLIXIZUMABCHEMBL4297820AntibodyApprovalEMA Human Drugs, FDA and PMDA1388Drugs and targets
NIPOCALIMABCHEMBL4594310AntibodyApprovalEMA Human Drugs644Drugs and targets
PYRIDOSTIGMINECHEMBL1115Small moleculeApprovalTTD433Drugs and targets
AMIFAMPRIDINE PHOSPHATECHEMBL3301611Small moleculeApprovalFDA322Drugs and targets
AMIFAMPRIDINECHEMBL354077Small moleculeApprovalDailyMed and FDA411Drugs and targets
NEOSTIGMINECHEMBL278020Small moleculeApprovalTTD211Drugs and targets
PYRIDOSTIGMINE BROMIDECHEMBL812Small moleculeApprovalDailyMed800Drugs and targets
NEOSTIGMINE METHYLSULFATECHEMBL211471Small moleculeApprovalDailyMed200Drugs and targets

1 to 10 of 77

See all 77 drugs

Targets115

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor8Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
ACHEAcetylcholinesterase7Acetylcholinesterase activator; Acetylcholinesterase inhibitorApprovalhttps://conductscience.org/library/genes/43Drugs and targets
C5Complement C56Complement C5 binding agent; Complement C5 inhibitor; Complement C5 mRNA RNAi inhibitorApprovalhttps://conductscience.org/library/genes/727Drugs and targets
FCGRTIgG receptor FcRn large subunit p515IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitorApprovalhttps://conductscience.org/library/genes/2217Drugs and targets
CSF3RGranulocyte colony-stimulating factor receptor4Granulocyte colony stimulating factor receptor agonistPhase 1https://conductscience.org/library/genes/1441Drugs and targets
KCNA1Voltage-gated potassium channel3Voltage-gated potassium channel blockerApprovalhttps://conductscience.org/library/genes/3736Drugs and targets
KCNA10Voltage-gated potassium channel3Voltage-gated potassium channel blockerApprovalhttps://conductscience.org/library/genes/3744Drugs and targets
KCNA2Voltage-gated potassium channel3Voltage-gated potassium channel blockerApprovalhttps://conductscience.org/library/genes/3737Drugs and targets
KCNA3Voltage-gated potassium channel3Voltage-gated potassium channel blockerApprovalhttps://conductscience.org/library/genes/3738Drugs and targets
KCNA4Voltage-gated potassium channel3Voltage-gated potassium channel blockerApprovalhttps://conductscience.org/library/genes/3739Drugs and targets

1 to 10 of 115

See all 115 targets

Trials105

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT04524273Myasthenia Gravis Inebilizumab TrialPhase 32382026-03-10Myasthenia GravisINEBILIZUMABIts record names the diseaseClinicalTrials.gov
NCT03971422A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisPhase 32002023-08-21Generalized Myasthenia GravisROZANOLIXIZUMABIts record names the diseaseClinicalTrials.gov
NCT04963270A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisPhase 31882025-02-28Generalized Myasthenia GravisSATRALIZUMABIts record names the diseaseClinicalTrials.gov
NCT04818671Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia GravisPhase 31842026-01-22Generalized Myasthenia GravisEFGARTIGIMOD ALFAIts record names the diseaseClinicalTrials.gov
NCT03920293Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia GravisPhase 31752022-05-26Generalized Myasthenia GravisRAVULIZUMABIts record names the diseaseClinicalTrials.gov
NCT04115293Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisPhase 31742023-01-17Myasthenia Gravis, GeneralizedZILUCOPLANIts record names the diseaseClinicalTrials.gov
NCT03669588An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessPhase 31672022-02-08Generalized Myasthenia GravisEFGARTIGIMOD ALFAIts record names the diseaseClinicalTrials.gov
NCT04650854A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisPhase 31652025-04-18Generalized Myasthenia GravisROZANOLIXIZUMABIts record names the diseaseClinicalTrials.gov
NCT03770403A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.Phase 31512023-07-14Generalized Myasthenia GravisEFGARTIGIMOD ALFAIts record names the diseaseClinicalTrials.gov
NCT00294658Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone TherapyPhase 31262017-01-16Myasthenia GravisPREDNISONEIts record names the diseaseClinicalTrials.gov

1 to 10 of 105

See all 105 trials

Comparisons in its trials46

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population1 of 1192 of 119238NCT04524273Trial comparisons
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population19 of 11941 of 117236NCT04524273Trial comparisons
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population
79 of 11555 of 114229NCT04524273Trial comparisons
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population83 of 9577 of 91186NCT04524273Trial comparisons
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population57 of 9561 of 91186NCT04524273Trial comparisons
Zilucoplan 0.3 mg/kg vs Placebo: deaths from any cause1 of 861 of 88174NCT04115293Trial comparisons
Zilucoplan 0.3 mg/kg vs Placebo: serious adverse events11 of 8613 of 88174NCT04115293Trial comparisons
ARGX-113 vs Placebo: deaths from any cause0 of 840 of 83167NCT03669588Trial comparisons
ARGX-113 vs Placebo: serious adverse events4 of 847 of 83167NCT03669588Trial comparisons
Thymectomy Plus Prednisone vs Prednisone Alone: Number of Patients With at Least One Serious Adverse Events25 of 6633 of 60126NCT00294658Trial comparisons

1 to 10 of 46

See all 46 comparisons in its trials

Papers from its trials95

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
42388397RESULT3PubMed
41205003RESULT1PubMed
41074934RESULT1PubMed
40755069RESULT1PubMed
40620733RESULT1PubMed
40504283RESULT2PubMed
39314260RESULT2PubMed
39297052RESULT1PubMed
38400914RESULT2PubMed
37763148RESULT1PubMed

1 to 10 of 95

See all 95 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009688

GET https://conductscience.org/api/diseases/v1/MONDO_0009688/drugs?page=2

API referenceFor AI assistants